MR
MRK
| Investor | Firm | Position | Weight | As of |
|---|---|---|---|---|
| Ken Fisher | Fisher Asset Management | $4,949M | 1.5% | 2026-06-30 |
| Saturna Capital | Amana Mutual Funds Trust | $25M | 0.3% | 2026-06-30 |
| Dodge & Cox | Dodge & Cox | $17M | 0.0% | 2026-06-30 |
| Azzad Asset Management | Azzad Asset Management | $11M | 1.0% | 2026-06-30 |
| Wahed Invest | Wahed Invest LLC | $8M | 0.8% | 2026-06-30 |
| Ray Dalio | Bridgewater Associates | $4M | 0.0% | 2026-06-30 |
| Thomas Russo | Gardner Russo & Quinn | $0M | 0.0% | 2026-06-30 |
From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.
Methodology breakdown computing — it will appear here on its own.
Merck & Co Inc (MRK) is currently considered halal (Sharia-compliant), per our secondary compliance provider (last assessed 2026-08-12). See the full ratio breakdown and business-activity screen below for the reasoning.
🕌 In-house Compliance Research
Computing the full ratio and business-activity breakdown for MRK — this runs off the critical path so the page paints first. It will appear here on its own.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
Price Forecast
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Technical Summary
Every indicator, and what it reads
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 52.50 | NEUTRAL |
| Stochastic %K (14) | 10.38 | BUY |
| CCI (20) | -44.10 | NEUTRAL |
| Williams %R (14) | -89.62 | BUY |
| MACD (12,26,9) | -1.33 | SELL |
| ROC (10) | -2.92 | SELL |
| Momentum (10) | -4.36 | SELL |
| EMA (10) | 147.66 | SELL |
| SMA (10) | 148.62 | SELL |
| EMA (20) | 145.77 | SELL |
| SMA (20) | 147.83 | SELL |
| EMA (30) | 142.95 | BUY |
| SMA (30) | 141.92 | BUY |
| EMA (50) | 138.03 | BUY |
| SMA (50) | 136.07 | BUY |
| EMA (100) | 129.69 | BUY |
| SMA (100) | 125.96 | BUY |
| EMA (200) | 118.08 | BUY |
| SMA (200) | 118.49 | BUY |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
About Merck & Co Inc
Healthcare · Drug Manufacturers - General
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
Background via Yahoo Finance — informational, not part of the verdict.
🟢 STRONG BUY SETUP
Strong confluence across multiple layers — outperforming the market by 12.9%, RSI in healthy zone, Wall Street broadly bullish. High conviction entry. Use `!plan MRK [entry] [stop] [target]` to size the position properly.
Scores: 4 bullish / 1 bearish
No real edge — avoid
SMC — Top Down
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | RANGING | 62 |
| ⏰ 4H | BEARISH | 50 |
| 🕐 1H | BEARISH | 98 |
| ⏱ 15-Min | RANGING | 130 |
| ⏲ 5-Min | BEARISH | 234 |
Momentum & Volume
Peer Movement
Peer movement computing — it will appear here on its own.
Insider Activity (90d)
CLUSTER SELL 0 buys · 17 sells
Recent: DeLuca Richard R. sold 160732 sh @ $131.02 (2026-08-06); DeLuca Richard R. sold 155487 sh @ $131.02 (2026-08-06); DeLuca Richard R. sold 155787 sh @ $130.23 (2026-08-06)
COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
AI Summary
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.